Skip to main content
SpringerLink
Log in

A Group of New Hypermethylated Long Non-Coding RNA Genes Associated with the Development and Progression of Breast Cancer

  • GENOMICS. TRANSCRIPTOMICS
  • Published:
Molecular Biology Aims and scope Submit manuscript

Abstract—Breast cancer is the most common type of cancer among women. The study of the mechanisms of metastasis, the main cause of death from breast cancer, as well as the search for new markers for early diagnosis and prognosis of breast cancer, is an extremely topical issue. New perspectives in the diagnosis and treatment of breast cancer are opened by the mechanisms of gene regulation involving non-coding RNAs, in particular, long non-coding RNAs (lncRNAs). In this work, we analyzed the methylation levels of seven lncRNA genes (MEG3, SEMA3B-AS1, HAND2-AS1, KCNK15-AS1, ZNF667-AS1, MAGI2-AS3, and PLUT) by quantitative methyl-specific PCR on a set of 79 paired (tumor/normal) samples of breast cancer. Hypermethylation of all seven lncRNA genes was revealed, and hypermethylation of HAND2-AS1, KCNK15-AS1, MAGI2-AS3, and PLUT was detected in breast cancer for the first time. It was found that the level of methylation of the studied lncRNA genes correlated statistically significantly with the stage of the tumor process, the size of the tumor, and the presence of metastases in the lymph nodes. Thus, methylation of the seven studied lncRNA genes is associated with the development and progression of breast cancer, and these genes can be useful as potential markers in the diagnosis and prognosis of breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.

REFERENCES

  1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. 2021. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71 (3), 209‒249. https://doi.org/10.3322/caac.21660

    Article  PubMed  Google Scholar 

  2. Cancer Genome Atlas Network 2012. Comprehensive molecular portraits of human breast tumours. Nature. 490 (7418), 61‒70. https://doi.org/10.1038/nature11412

    Article  CAS  ADS  Google Scholar 

  3. Cuzick J. 2017. Preventive therapy for cancer. Lancet Oncol. 18 (8), 472‒482. https://doi.org/10.1016/S1470-2045(17)30536-3

    Article  Google Scholar 

  4. Harbeck N., Gnant M. 2017. Breast cancer. Lancet. 389 (10074), 1134‒1150. https://doi.org/10.1016/S0140-6736(16)31891-8

    Article  PubMed  Google Scholar 

  5. Rahman M.M., Brane A.C., Tollefsbol T.O. 2019. MicroRNAs and epigenetics strategies to reverse breast cancer. Cells. 8 (10), 1214. https://doi.org/10.3390/cells8101214

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Sharma S., Kelly T.K., Jones P.A. 2010. Epigenetics in cancer. Carcinogenesis. 31 (1), 27‒36. https://doi.org/10.1093/carcin/bgp220

    Article  CAS  PubMed  Google Scholar 

  7. Rose M., Kloten V., Noetzel E., Gola L., Ehling J., Heide T., Meurer S.K., Gaiko-Shcherbak A., Sechi A.S., Huth S., Weiskirchen R., Klaas O., Antonopoulos W., Lin Q, Wagner W., Veeck J., Gremse F., Steitz J., Knüchel R., Dahl E. 2017. ITIH5 mediates epigenetic reprogramming of breast cancer cells. Mol. Cancer. 16 (1), 44. https://doi.org/10.1186/s12943-017-0610-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Jeong G.Y., Park M.K., Choi H.J., An H.W., Park Y.U., Choi H.J., Park J., Kim H.Y., Son T., Lee H., Min K.W., Oh Y.H., Lee J.Y., Kong G. 2021. NSD3-Induced methylation of H3K36 activates NOTCH signaling to drive breast tumor initiation and metastatic progression. Cancer Res. 81 (1), 77‒90. https://doi.org/10.1158/0008-5472.CAN-20-0360

    Article  CAS  PubMed  Google Scholar 

  9. Klinge C.M. 2018. Non-coding RNAs: Long non-coding RNAs and microRNAs in endocrine-related cancers. Endocr. Relat. Cancer. 25 (4), 259‒282. https://doi.org/10.1530/ERC-17-0548

    Article  Google Scholar 

  10. Venkatesh J., Wasson M.D., Brown J.M., Fernando W., Marcato P. 2021. LncRNA-miRNA axes in breast cancer: Novel points of interaction for strategic attack. Cancer Lett. 509, 81‒88. https://doi.org/10.1016/j.canlet.2021.04.002

    Article  CAS  PubMed  Google Scholar 

  11. Fazal F.M., Chang H.Y. 2016. lncRNA structure: Message to the heart. Mol. Cell. 64 (1), 1‒2. https://doi.org/10.1016/j.molcel.2016.09.030

    Article  CAS  PubMed  Google Scholar 

  12. Kim J., Piao H.L., Kim B.J., Yao F., Han Z., Wang Y., Xiao Z., Siverly A.N., Lawhon S.E., Ton B.N., Lee H., Zhou Z., Gan B., Nakagawa S., Ellis M.J., Liang H., Hung M.C., You M.J., Sun Y., Ma L. 2018. Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nat. Genet. 50 (12), 1705‒1715. https://doi.org/10.1038/s41588-018-0252-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Slack F.J., Chinnaiyan A.M. 2019. The role of non-coding RNAs in oncology. Cell. 179 (5), 1033‒1055. https://doi.org/10.1016/j.cell.2019.10.017

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Hazra A., Bose P., Sunita P., Pattanayak S.P. 2021. Molecular epigenetic dynamics in breast carcinogenesis. Arch. Pharm. Res. 44 (8), 741‒763. https://doi.org/10.1007/s12272-021-01348-0

    Article  CAS  PubMed  Google Scholar 

  15. Wu H.J., Chu P.Y. 2021. Epigenetic regulation of breast cancer stem cells contributing to carcinogenesis and therapeutic implications. Int. J. Mol. Sci. 22 (15), 8113. https://doi.org/10.3390/ijms22158113

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Cheetham S.W., Gruhl F., Mattick J.S., Dinger M.E. 2013. Long noncoding RNAs and the genetics of cancer. Br. J. Cancer. 108 (12), 2419‒2425. https://doi.org/10.1038/bjc.2013.233

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Huang J., Zhang S.Y., Gao Y.M., Liu Y.F., Liu Y.B., Zhao Z.G., Yang K. 2014. MicroRNAs as oncogenes or tumour suppressors in oesophageal cancer: Potential biomarkers and therapeutic targets. Cell Prolif. 47 (4), 277‒286. https://doi.org/10.1111/cpr.12109

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Union for International Cancer Control (UICC) 2017. TNM Classification of Malignant Tumours. Eds Brierley J.D., Gospodarowicz M.K., Wittekind C. Oxford, UK: Wiley.

    Google Scholar 

  19. World Medical Association 2013. World Medical Association declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 310 (20), 2191‒2194. https://doi.org/10.1001/jama.2013.281053

    Article  CAS  Google Scholar 

  20. Loginov V.I., Pronina I.V., Filippova E.A., Burdennyy A.M., Lukina S.S., Kazubskaya T.P., Uroshlev L.A., Fridman M.V., Brovkina O.I., Apanovich N.V., Karpukhin A.V., Stilidi I.S., Kushlinskii N.E., Dmitriev A.A., Braga E.A. 2022. Aberrant methylation of 20 miRNA genes specifically involved in various steps of ovarian carcinoma spread: From primary tumors to peritoneal macroscopic metastases. Int. J. Mol. Sci. 23 (3), 1300. https://doi.org/10.3390/ijms23031300

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Hattermann K., Mehdorn H.M., Mentlein R., Schultka S., Held-Feindt J. 2008. A methylation-specific and SYBR-green-based quantitative polymerase chain reaction technique for O6-methylguanine DNA methyltransferase promoter methylation analysis. Anal. Biochem. 377 (1), 62‒71. https://doi.org/10.1016/j.ab.2008.03.014

    Article  CAS  PubMed  Google Scholar 

  22. Selezneva A.D., Filippova E.A., Selezneva A.D., Lukina S.S., Pronina I.V., Ivanova N.A., Kazubskaya T.P., Burdennyy A.M., Braga E.A., Loginov V.I. 2022. Hypermethylation of long non-coding RNA genes group in the breast cancer development and progression. Bull. Exp. Biol. Med. 173 (6), 765‒769. https://doi.org/10.1007/s10517-022-05627-8

    Article  CAS  PubMed  Google Scholar 

  23. Vrba L., Futscher B.W. 2017. Epigenetic silencing of MORT is an early event in cancer and is associated with luminal, receptor positive breast tumor subtypes. J. Breast Cancer. 20 (2), 198‒202. https://doi.org/10.4048/jbc.2017.20.2.198

    Article  PubMed  PubMed Central  Google Scholar 

  24. Di Fiore R., Suleiman S., Drago-Ferrante R., Felix A., OꞌToole S.A., O’Leary J.J., Ward M.P., Beirne J., Yordanov A., Vasileva-Slaveva M., Subbannayya Y., Pentimalli F., Giordano A., Calleja-Agius J. 2021. LncRNA MORT (ZNF667-AS1) in cancer—is there a possible role in gynecological malignancies? Int. J. Mol. Sci. 22 (15), 7829. https://doi.org/10.3390/ijms22157829

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Li H., Wang P., Liu J., Liu W., Wu X., Ding J., Kang J., Li J., Lu J., Pan G. 2020. Hypermethylation of lncRNA MEG3 impairs chemosensitivity of breast cancer cells. J. Clin. Lab. Anal. 34 (9), e23369. https://doi.org/10.1002/jcla.23369

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Burdennyy A.M., Filippova E.A., Ivanova N.A., Lukina S.S., Pronina I.V., Loginov V.I., Fridman M.V., Kazubskaya T.P., Utkin D.O., Braga E.A., Kushlinskii N.E. 2021. Hypermethylation of genes in new long noncoding RNA in ovarian tumors and metastases: A dual effect. Bull. Exp. Biol. Med. 171 (3), 370–374. https://doi.org/10.1007/s10517-021-05230-3

    Article  CAS  PubMed  Google Scholar 

  27. Hu J., Huang H., Xi Z., Ma S., Ming J., Dong F., Guo H., Zhang H., Zhao E., Yao G., Yang L., Zhang F., Zheng W., Chen H., Huang T., Li L. 2022. LncRNA SEMA3B-AS1 inhibits breast cancer progression by targeting miR-3940/KLLN axis. Cell Death Dis. 13 (9), 800. https://doi.org/10.1038/s41419-022-05189-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Yu C., Chen W., Cai Y., Du M., Zong D., Qian L., Jiang X., Zhu H. 2022. The lncRNA ZNF667-AS1 inhibits propagation, invasion, and angiogenesis of gastric cancer by silencing the expression of N-cadherin and VEGFA. J. Oncol. 2022–3579547. https://doi.org/10.1155/2022/3579547

  29. Yang X., Wang C.C., Lee W.Y.W., Trovik J., Chung T.K.H, Kwong J. 2018. Long non-coding RNA HAND2-AS1 inhibits invasion and metastasis in endometrioid endometrial carcinoma through inactivating neuromedin U. Cancer Lett. 28 (413), 23–34. https://doi.org/10.1016/j.canlet.2017.10.028

    Article  CAS  Google Scholar 

  30. Gokulnath P., de Cristofaro T., Manipur I., Di Palma T., Soriano A.A., Guarracino M.R., Zannini M. 2020. Long non-coding RNA HAND2-AS1 acts as a tumor suppressor in high-grade serous ovarian carcinoma. Int. J. Mol. Sci. 21 (11), 4059. https://doi.org/10.3390/ijms21114059

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Zhang H., Zhang Z., Wang D. 2019. Epigenetic regulation of lncRNA KCNKI5-ASI in gastric cancer. Cancer Manage. Res. 11, 8589–8602. https://doi.org/10.2147/CMAR.S186002

    Article  CAS  Google Scholar 

  32. Wang J., Yang C., Cao H., Yang J., Meng W., Yu M., Yu L., Wang B. 2023. Hypermethylation-mediated lncRNA MAGI2-as3 downregulation facilitates malignant progression of laryngeal squamous cell carcinoma via interacting with SPT6. Cell Transplant. 32 (9636897231154574). https://doi.org/10.1177/09636897231154574

  33. Kim-Wanner S.Z., Assenov Y., Nair M.B., Weichenhan D., Benner A., Becker N., Landwehr K., Kuner R., Sültmann H., Esteller M., Koch I., Lindner M., Meister M., Thomas M., Bieg M., Klingmüller U., Schlesner M., Warth A., Brors B., Seifried E., Bönig H., Plass C., Risch A., Muley T. 2020. Genome-wide DNA methylation profiling in early stage I lung adenocarcinoma reveals predictive aberrant methylation in the promoter region of the long noncoding RNA PLUT: An exploratory study. J. Thorac. Oncol. 15 (8), 1338–1350. https://doi.org/10.1016/j.jtho.2020.03.023

    Article  CAS  PubMed  Google Scholar 

  34. Al-Rugeebah A., Alanazi M., Parine N.R. 2019. MEG3: An oncogenic long non-coding RNA in different cancers. Pathol. Oncol. Res. 25 (3), 859–874. https://doi.org/10.1007/s12253-019-00614-3

    Article  CAS  PubMed  Google Scholar 

  35. Zhang W., Shi S., Jiang J., Li X., Lu H., Ren F. 2017. LncRNA MEG3 inhibits cell epithelial-mesenchymal transition by sponging miR-421 targeting E-cadherin in breast cancer. Biomed. Pharmacother. 91, 312–319. https://doi.org/10.1016/j.biopha.2017.04.085

    Article  CAS  PubMed  Google Scholar 

  36. Zhang L., Liang X., Li Y. 2017. Long non-coding RNA MEG3 inhibits cell growth of gliomas by targeting miR-93 and inactivating PI3K/AKT pathway. Oncol. Rep. 38 (4), 2408–2416. https://doi.org/10.3892/or.2017.5871

    Article  CAS  PubMed  Google Scholar 

  37. Chen X., Huang Y., Shi D., Nie C., Luo Y., Guo L., Zou Y., Xie C. 2020. LncRNA ZNF667-AS1 promotes ABLIM1 expression by adsorbing microRNA-1290 to suppress nasopharyngeal carcinoma cell progression. OncoTargets Ther. 20 (13), 4397–4409. https://doi.org/10.2147/OTT.S245554

    Article  Google Scholar 

  38. Zhuang L., Ding W., Ding W., Zhang Q., Xu X., Xi D. 2021. lncRNA ZNF667-AS1 (NR_036521.1) inhibits the progression of colorectal cancer via regulating ANK2/JAK2 expression. J. Cell. Physiol. 236 (3), 2178–2193. https://doi.org/10.1002/jcp.30004

    Article  CAS  PubMed  Google Scholar 

  39. Yang Y., Yang H., Xu M., Zhang H., Sun M., Mu P., Dong T., Du S., Liu K. 2018. Long non-coding RNA (lncRNA) MAGI2-AS3 inhibits breast cancer cell growth by targeting the Fas/FasL signalling pathway. Hum. Cell. 31 (3), 232–241. https://doi.org/10.1007/s13577-018-0206-1

    Article  CAS  PubMed  Google Scholar 

  40. Hu R., Wu P., Liu J. 2022. LncRNA MAGI2-AS3 inhibits prostate cancer progression by targeting the miR-142-3p. Hormon. Metab Res. 54 (11), 754–759. https://doi.org/10.1055/a-1891-6864

    Article  CAS  Google Scholar 

  41. Wang F., Zu Y., Zhu S., Yang Y., Huang W., Xie H., Li G. 2018. Long noncoding RNA MAGI2-AS3 regulates CCDC19 expression by sponging miR-15b-5p and suppresses bladder cancer progression. Biochem Biophys Res Commun. 507 (1–4), 231–235. https://doi.org/10.1016/j.bbrc.2018.11.013

    Article  CAS  PubMed  Google Scholar 

  42. Yin Z., Ma T., Yan J., Shi N., Zhang C., Lu X., Hou B., Jian Z. 2019. LncRNA MAGI2-AS3 inhibits hepatocellular carcinoma cell proliferation and migration by targeting the miR-374b-5p/SMG1 signaling pathway. J. Cell Physiol. 234 (10), 18825–18836. https://doi.org/10.1002/jcp.28521

    Article  CAS  PubMed  Google Scholar 

  43. Sui Y., Chi W., Feng L., Jiang J. 2020. LncRNA M-AGI2-AS3 is downregulated in non-small cell lung cancer and may be a sponge of miR-25. BMC Pulmonol. Med. 20 (1), 59. https://doi.org/10.1186/s12890-020-1064-7

    Article  CAS  Google Scholar 

  44. Li D., Wang J., Zhang M., Hu X., She J., Qiu X., Zhang X., Xu L., Liu Y, Qin S. 2020. LncRNA -MAGI2-AS3 is regulated by BRD4 and promotes gastric cancer progression via maintaining ZEB1 overexpression by sponging miR-141/200a. Mol. Ther. Nucleic Acids. 19, 109–123. https://doi.org/10.1016/j.omtn.2019.11.003

    Article  CAS  PubMed  Google Scholar 

  45. Dong G., Wang X., Jia Y., Jia Y., Zhao W., Zhang J., Tong Z. 2020. HAND2-AS1 works as a ceRNA of miR-3118 to suppress proliferation and migration in breast cancer by upregulating PHLPP2. Biomed. Res. Int., 2020. 8124570. https://doi.org/10.1155/2020/8124570

  46. Jiang Z., Li L., Hou Z., Liu W., Wang H., Zhou T., Li Y., Chen S. 2020. LncRNA HAND2-AS1 inhibits 5-fuorouracil resistance by modulating miR-20a/PD-CD4 axis in colorectal cancer. Cell. Signal. 66, 109483.

    Article  CAS  PubMed  Google Scholar 

  47. Yan Y., Li S., Wang S., Rubegni P., Tognetti L., Zhang J., Yan L. 2019. Long noncoding RNA HAND2-AS1 inhibits cancer cell proliferation, migration, and invasion in esophagus squamous cell carcinoma by regulating microRNA-21. J. Cell. Biochem. 120 (6), 9564–9571.

    Article  CAS  PubMed  Google Scholar 

  48. Chen J., Lin Y., Jia Y., Xu T., Wu F., Jin Y. 2019. L-ncRNA HAND2-AS1 exerts antioncogenic effects on ovarian cancer via restoration of BCL2L11 as a sponge of microRNA-340-5p. J. Cell. Physiol. 234, 23421–23436. https://doi.org/10.1002/jcp.28911

    Article  CAS  PubMed  Google Scholar 

  49. Wang Y., Zhu P., Luo J., Wang J., Liu Z., Wu W., Du Y., Ye B., Wang D., He L., Ren W., Wang J., Sun X., Chen R., Tian Y., Fan Z. 2019. LncRNA HAND2-AS1 promotes liver cancer stem cell self-renewal via BMP signaling, EMBO J. 38 (17), e101110. https://doi.org/10.15252/embj.2018101110

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. He Y., Yue H., Cheng Y., Ding Z., Xu Z., Lv C., Wang Z., Wang J., Yin C., Hao H., Chen C. 2021. ALKBH5-mediated m6A demethylation of KCNK15-AS1 inhibits pancreatic cancer progression via regulating KCNK15 and PTEN/AKT signaling. Cell Death Dis. 12 (12), 1121. https://doi.org/10.1038/s41419-021-04401-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Peng J., Chen X.L., Cheng H.Z., Xu Z.Y., Wang H., Shi Z.Z., Liu J., Ning X.G., Peng H. 2019. Silencing of KCNK15-AS1 inhibits lung cancer cell proliferation via upregulation of miR-202 and miR-370. Oncol. Lett. 18 (6), 5968–5976. https://doi.org/10.3892/ol.2019.10944

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Zhang J., Yao T., Lin Z., Gao Y. 2017. Aberrant methylation of MEG3 functions as a potential plasma-based biomarker for cervical cancer. Sci. Rep. 7 (1), 6271. https://doi.org/10.1038/s41598-017-06502-7

    Article  CAS  ADS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

The work was carried out at the expense of the Russian Science Foundation (grant No. 22-75-00132).

Author information

Authors and Affiliations

  1. Institute of General Pathology and Pathophysiology, 125315, Moscow, Russia

    E. A. Filippova, V. I. Loginov, S. S. Lukina, A. M. Burdennyy, I. V. Pronina & E. A. Braga

  2. Blokhin National Medical Research Center of Oncology, 115478, Moscow, Russia

    T. P. Kazubskaya

Authors
  1. E. A. Filippova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. I. Loginov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. S. Lukina
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. M. Burdennyy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. V. Pronina
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. P. Kazubskaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E. A. Braga
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. A. Filippova.

Ethics declarations

CONFLICT OF INTEREST

The authors of this work declare that they have no conflicts of interest.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

All procedures performed in this work are in accordance with the ethical standards of the Institutional Research Ethics Committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was considered and approved by the local Ethics Committee of the Institute of General Pathology and Pathophysiology (protocols No. 1 dated March 3, 2022 and No. 4 dated August 31, 2023). All patients received written informed consent to participate in the work.

Additional information

Publisher’s Note.

Pleiades Publishing remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Filippova, E.A., Loginov, V.I., Lukina, S.S. et al. A Group of New Hypermethylated Long Non-Coding RNA Genes Associated with the Development and Progression of Breast Cancer. Mol Biol 58, 71–80 (2024). https://doi.org/10.1134/S0026893324010035

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S0026893324010035

Keywords:

Search

Navigation